Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick(German Cancer Research Center), Martin J. van den Bent(Erasmus MC Cancer Institute), Martin Bendszus(Heidelberg University), Jacoline C. Bromberg(Heidelberg University), Walter Taal(Heidelberg University), Martin Klein(Amsterdam University Medical Centers), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Julien Dômont(Heidelberg University), Andreas von Deimling(German Cancer Research Center), Inga Harting(Heidelberg University), Roger Stupp(Northwestern University), Martin Taphoorn(Leiden University Medical Center), Felix Sahm(German Cancer Research Center), Michael Platten(German Cancer Research Center), Mario Campone(Institut de Cancérologie de l'Ouest), Émilie Le Rhun(University of Zurich), Michel Fabbro(Nordic Society of Gynecologic Oncology), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Ahmed Idbaïh(Centre National de la Recherche Scientifique), Vassilis Golfinopoulos(Champalimaud Foundation), Paul M. Clément(Universitair Ziekenhuis Leuven), François Dubois(Hôpital Roger Salengro), Michael Weller(University Hospital of Zurich)
Cited by 994
Related Papers
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k